of example as compared with cimetidine 1 test study of gastric secretion by ligature of the pylorus using shay 39 s technique gastroenterology 5 53 1945 and 26 906 1954 on male sprague dawley rats acute treatment by intraduodenal route in a dose of 50 mg kg ______________________________________ variation decrease of the increase of theproduct volume secreted intragastric ph______________________________________cimetidine 47 901 76 1587 70 1184 76 26716 79 15315 50 181______________________________________ 2 activity toward ulcers with acetyl salicylic acid quantified in accordance with the pfeiffer scale arch int pharmacodyn 190 5 13 1971 on male rats treatment orally acute ______________________________________ inhibition dose of theproduct mg kg ulcer lesions______________________________________cimetidine 40 46 1 40 34 7 40 4612 40 4015 50 3516 50 32______________________________________ based on their pharmacological properties the compounds of the invention can be used in the treatment of digestive pathology and more particularly of ulcer pathology the pharmaceutical preparations containing these active principles can be administered orally it is also possible to combine therewith other pharmaceutically and therapeutically acceptable active principles those compounds of the present invention comprising a salt forming group can be administered to man or animal orally or parenterally in the form either of the free base or in the form of a therapeutically acceptable salt the new derivatives which are bases can be converted into acid addition salts with acids which acid addition salts form part of the invention these acid addition salts can be obtained by reaction of the new basic derivatives with an acid in a suitable solvent such as for example in the mineral acid series hydrochloric hydrobromic methanesulphonic sulphuric and phosphoric and in the organic series acetic.